Cancer chemoprevention: A rapidly evolving field

British Journal of Cancer

Volumn 109, Issue 1, 2013, Pages 1-7

  Steward, W P ^a   Brown, K ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANASTROZOLE; ANTINEOPLASTIC AGENT; BETA CAROTENE; CELECOXIB; DUTASTERIDE; EXEMESTANE; FINASTERIDE; ICOSAPENTAENOIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RALOXIFENE; SELENIUM; TAMOXIFEN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER MODEL; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFICACY; DRUG INDICATION; DRUG PREFERENCE; DRUG RESEARCH; ENDOMETRIUM CARCINOMA; ENDOMETRIUM TUMOR; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; STUDY DESIGN; THROMBOEMBOLISM;

ANTICARCINOGENIC AGENTS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880300172     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.280     Document Type: Review

References (51)

1. Abate-Shen C, Brown PH, Colburn NH, Gerner EW, Green JE, Lipkin M, Nelson WG, Threadgill D (2008) The untapped potential of genetically engineered mouse models in chemoprevention research: opportunities and challenges. Cancer Prev Res 1: 161-166.
2. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, Hartman AM, Palmgren J, Freedman LS, Haapakoski J, Barrett MJ, Pietinen P, Malila N, Tala E, Liippo K, Salomaa ER, Tangrea JA, Teppo L, Askin FB, Taskinen E, Erozan Y, Greenwald P, Huttunen JK (1996) a-Tocopherol and b-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88: 1560-1570.
3. Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13: 518-527.
4. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. REDUCE Study Group (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192-1202.
5. Brown VA, Patel K, Viskaduraki M, Crowell J, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE (2010) Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011.
6. Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard M-L, Dunlop MG, Ho JWC, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJW, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT. CAPP2 Investigators (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378: 2081-2087.
7. Cohen PA (2012) Assessing supplement safety: the FDA's controversial proposal. N Engl J Med 366: 389-391.
8. Crowell JA (2005) The chemopreventive agent development research program in the Division of Cancer prevention of the US National Cancer Institute: an overview. Eur J Cancer 41: 1889-1910.
9. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A. International Breast Cancer Intervention Study I Investigators (2007) Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99: 272-282.
10. De Flora S, Ferguson LR (2005) Overview of mechanisms of cancer chemopreventive agents. Mutat Res 591: 8-15.
11. Din FVN, Valanciute A, Houde VP, Zibrova D, Green KA, Sakamoto K, Alessi DR, Dunlop MG (2012) Aspirin inhibits mTOR signaling, activates AMPactivated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology 142: 1504-1515.
12. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs Jr GF, Slate EH, Fischbach LA, Marshall JR, Clark LC (2002) Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630-639.
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388.
14. Flossman E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613.
15. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
16. Gerhauser C, Bartsch H, Crowell J, De Flora S, D0Incali M, Dittrich C, Frank N, Mihich E, Steffen C, Tortora G, Gescher A (2006) Development of novel cancer chemopreventive agents in Europe-neglected Cinderella or rising phoenix? ESF workshop on cancer chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. Eur J Cancer 42: 1338-1343.
17. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H. NCIC CTG MAP.3 Study Investigators (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364: 2381-2391.
18. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
19. Harris RE, Chelbowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A (2003) Women's health initiative. breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women's health initiative. Cancer Res 63: 6096-6101.
20. Hauser A-T, Jung M (2008) Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Medica 74: 1593-1601.
21. Karin M (2006) Nuclear factor-kB in cancer development and progression. Nature 441: 431-436.
22. Kelloff GJ, Johnson JR, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G, Greenwald P, Temple RJ (1995) Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4: 1-10.
23. Klein EA, Thompson Jr IM, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens Jr FL, Baker LH (2011) Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549-1556.
24. Kummar S, Doroshow JH (2011) Phase 0 trials: expediting the development of chemoprevention agents. Cancer Prev Res 4: 288-292.
25. Lippman SM, Benner SE, Hong WK (1994) Cancer chemoprevention. J Clin Oncol 12: 851-873.
26. Lippman SM, Hong WK (2002) Cancer prevention by delay. Commentary re: J A O'Shaughnessy et al., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8: 305-313.
27. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden III JD, Grawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL, Baker LH, Coltman Jr CA (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Amer Med Ass 301: 39-51.
28. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman Jr CA, Thompson IM (2007) Finasteride and highgrade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99: 1375-1383.
29. Meyskens Jr FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebocontrolled, double-blind trial. Cancer Prev Res 1: 32-38.
30. National Center for Health Statistics, Centers for Disease Control and Prevention (2005) US Mortality Data, 1960 to 2004
31. National Center for Health Statistics. Centers for Disease Control and Prevention US Government publication.
32. National Cancer Institute (2008) The Early Detection Research Network: investing in translational research on biomarkers of early cancer and cancer risk. Fourth Report. U.S. Department of Health and Human Services. National Institutes of Health: Bethesda, MD.
33. Noonan DM, Benelli R, Albini A (2007) Angiogenesis and cancer prevention: a vision. Recent Results in Cancer Res 174: 219-224.
34. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens Jr FL, Valanis B, Williams Jr JH, Barnhart S, Hammar S (1996) Effects of a combination of b carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155.
35. Rothwell PM, Price JF, Fowkes GR, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JFF, Wilson M, Mehta Z, Meade TW (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612.
36. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750.
37. Scott EN, Gescher AJ, Steward WP, Brown K (2009) Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res 2: 525-530.
38. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
39. Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36: 2699-2702.
40. Steering Committee of the Physicians' Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321: 129-135.
41. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952.
42. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035.
43. Thompson IM, Goodman PJ, Tangen CM, Scott Lucia M, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224.
44. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84.
45. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon Jr ER, Wade 3rd JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741.
46. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade 3rd JL, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill- Stevens W, Ford LG, Jordan VC, Wolmark N. National Surgical Adjuvant Breast and Bowel Project (2010) Update of the National Surgical Adjuvant breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 3: 696-706.
47. West NJ, Clark SK, Phillips RKS, Hutchinson JM, Leicester RJ, Belluzzi A, Hull MA (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 59: 918-925.
48. Wu X, Lippman SM (2011b) An intermittent approach for cancer chemoprevention. Nat Rev Cancer 11: 879-885.
49. Wu X, Patterson S, Hawk E (2011a) Chemoprevention-history and general principles. Best Pract Res Clin Gastroenterol 25: 445-459.
50. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
51. Yu S, Kong A-NT (2007) Targeting carcinogen metabolism by dietary cancer preventive compounds. Curr Cancer Drug Targets 7: 416-424.